Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

MTNB vs VTVT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MTNB Captures Overall Composite Edge (54.6 HOLD vs 38.9 SELL), While VTVT Leads 4–1 on Growth & Valuation Pillars

MTNB Overall Winner 6-Pillar Tally: MTNB 1 – 4 VTVT (1 Tie) Matrix Metrics: MTNB 4 – 4 VTVT

As of Nov 19, 2026, Matinas BioPharma Holdings, Inc. (MTNB) captures the overall head-to-head institutional edge over vTv Therapeutics Inc. (VTVT) on higher Unified Composite conviction (54.6/100 HOLD vs. 38.9/100 SELL) after splitting the core matrix 4–4 (led by Profitability & Quality), while VTVT wins 4–1 across the 6-pillar growth and valuation breakdown. MTNB trades at $0.81 (N/M Forward P/E, 0.0% operating margin) versus VTVT at $16.36 (N/M Forward P/E, -29.8% operating margin).

  • Growth vs. Quality Trade-Off: MTNB earns the overall head-to-head edge with a stronger Unified Composite Score (54.6/100 HOLD vs. VTVT 38.9/100 SELL) and -7.20β · 147% Vol risk profile, whereas VTVT leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: MTNB trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 33.0); meanwhile VTVT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 17.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MTNB vs VTVT
MTNB NYSE American Head-to-Head Winner
Matinas BioPharma Holdings, Inc.
Pharmaceutical Preparations
$0.81
-10.98% 1D
Market Cap $979,904
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -7.20β · 147% Vol
Unified Composite Score
54.6 / 100 HOLD
Tech 53.0 Fund 58.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 33
RSI-14: 33.0 · SMA20: $1.26 · SMA50: $1.47
VTVT NASDAQ
vTv Therapeutics Inc. Class A Common Stock
Pharmaceutical Preparations
$16.36
+0.8% 1D
Market Cap $65.5M
TTM Revenue $37M
Forward P/E N/M
Beta / 30D Vol 1.51β · 55% Vol
Unified Composite Score
38.9 / 100 SELL
Tech 25.0 Fund 42.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -13.6%), weak momentum, RSI 17
RSI-14: 17.4 · SMA20: $22.02 · SMA50: $26.77

6-Pillar Scorecard Institutional Category Breakdown (MTNB 1 – 4 VTVT)

Columns: Metric · MTNB · VTVT
1. Valuation Multiples VTVT
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 1.8x
2. Growth & Scale VTVT
Revenue Growth (YoY) -100.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $37M
Market Cap $979,904 $65.5M
3. Profitability & Quality MTNB
Gross Margin N/A 20.8%
Operating Margin 0.0% -29.8%
Net Profit Margin 0.0% -20.8%
Return on Equity (ROE) -147.5% -10.9%
4. Balance Sheet & Cash Flow VTVT
Cash Generation (TTM) N/A -$11M EBITDA
Cash Flow Margin N/A -29.8% EBITDA Mgn
Net Cash / Leverage $1.2M Net Cash $5.60 Book/Sh · -10.9% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat VTVT
OpEx & R&D Intensity N/A 50.6% of Rev ($19M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MTNB (4) vs VTVT (4)
Institutional Metric MTNB VTVT Criterion Row Edge
Market Capitalization
Scale
$979,904 $65.5M Larger Scale VTVT
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-100.0% +0.0% Higher Growth VTVT
Operating Margin (TTM)
Profitability
0.0% -29.8% Higher Margin MTNB
Net Profit Margin
Profitability
0.0% -20.8% Higher Margin MTNB
Return on Equity (ROE)
Capital Efficiency
-147.5% -10.9% Higher ROE VTVT
52-Week Range Position
Momentum
22% ($0–$3) 2% ($16–$44) Stronger Trend MTNB
Beta / 30D Volatility
Risk Regime
-7.20β · 147% Vol 1.51β · 55% Vol Lower Realized Risk VTVT
Unified Institutional Score
Composite Signal
54.6 / 100 (HOLD) 38.9 / 100 (SELL) Higher Composite MTNB
Trailing 12M Revenue (USD)
Operating Scale
N/A $37M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 20.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 1.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($1.2M Net Cash) -$11M EBITDA ($5.60 Book/Sh · -10.9% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VTVT +5.61 pp
MTNB: -46.7% · VTVT: -41.09%
3M Horizon MTNB +358.29 pp
MTNB: +307.49% · VTVT: -50.8%
6M Horizon MTNB +74.85 pp
MTNB: +20.93% · VTVT: -53.92%
1Y Horizon MTNB +14.32 pp
MTNB: -31.35% · VTVT: -45.67%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MTNB vs VTVT. Trailing 12-month operating profitability (MTNB 0.0% vs VTVT -29.8%) and valuation multiples (MTNB N/M vs VTVT N/M Forward P/E) are benchmarked directly in Pillar 4 below.

MTNB ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-147.5% · N/M
VTVT ADR TTM Benchmark FX-Normalized USD
TTM Revenue$37M
Gross Margin20.8%
Op. Margin-29.8%
ROE / Fwd P/E-10.9% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MTNB UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MTNB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VTVT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VTVT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MTNB Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $979,904 market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
VTVT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $65.5M market capitalization and -29.8% operating margin.
OpEx & R&D Reinvestment 50.6% of Rev ($19M)
90D Engineering Disclosures 0 Published

Investor FAQ MTNB vs VTVT Key Questions & Quantitative Answers

As of Nov 19, 2026, Matinas BioPharma Holdings, Inc. (MTNB) captures the overall head-to-head institutional edge over vTv Therapeutics Inc. (VTVT) on higher Unified Composite conviction (54.6/100 HOLD vs. 38.9/100 SELL) after splitting the core matrix 4–4 (led by Profitability & Quality), while VTVT wins 4–1 across the 6-pillar growth and valuation breakdown. MTNB trades at $0.81 (N/M Forward P/E, 0.0% operating margin) versus VTVT at $16.36 (N/M Forward P/E, -29.8% operating margin). Growth vs. Quality Trade-Off: MTNB earns the overall head-to-head edge with a stronger Unified Composite Score (54.6/100 HOLD vs. VTVT 38.9/100 SELL) and -7.20β · 147% Vol risk profile, whereas VTVT leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: MTNB trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 33.0); meanwhile VTVT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 17.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VTVT leads the Growth & Scale pillar: MTNB posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with VTVT at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $37M TTM revenue (20.8% gross margin, -29.8% operating margin). On trailing 12-month operating scale, MTNB generates N/A in USD-normalized revenue versus $37M for VTVT. In operating R&D and SG&A reinvestment, MTNB deploys N/A (0 90-day corporate R&D disclosures) versus 50.6% of Rev ($19M) (0 disclosures) for VTVT.

VTVT screens cheaper on headline valuation multiples. MTNB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas VTVT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.8x EV/Revenue (-29.8% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MTNB (-147.5% ROE) versus VTVT (-10.9% ROE) capital efficiency.

In options market volatility and institutional positioning, MTNB carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-7.20β · 147% Vol realized risk). By comparison, VTVT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.51β · 55% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.